<DOC>
	<DOCNO>NCT02591030</DOCNO>
	<brief_summary>Bile duct tumour rare . They 6th common type digestive cancer . Their therapeutic management complex must multidisciplinary nature . Most time , endoscopic radiological biliary drainage necessary tumour treatment . Their prognosis poor due fact normally diagnose late , make curative surgery impossible . A population study Côte d'Or region France report survival rate 5 year approximately 10 % . For locally advanced metastatic form , treatment properly codify . With respect chemotherapy , prospective study , often phase II , difficult interpret due limited number patient due heterogeneity type tumour ( bile duct pancreas tumours ) . Treatment 5FU alone provide objective response approximately 10 % case . In combination mitomycin carboplatin , objective response rate 20 % , median survival period 5 month . Interferon combine 5FU good response rate ( 30 % ) , occurrences different type toxicity frequent . More recently , gemcitabine 5FU-cisplatin combination demonstrate objective tumour control 50 % patient median survival period 10 month . Gemcitabine combine oxiplatin cisplatin show response rate median survival period approximately 12 month . The benefit combination confirm phase III trial compare gemcitabine-cisplatin combination gemcitabine alone , 410 patient locally advance unresectable and/or metastatic bile duct cancer . The result favour combined treatment median survival period 11.7 month ( versus 8.1 month - HR 0.64 [ 0.52 - 0.80 ] ) . This combination currently reference first-line treatment .</brief_summary>
	<brief_title>Safety Efficacy Modified Folfirinox Versus Gemcis Bile Duct Tumours</brief_title>
	<detailed_description>At time result , triple therapy involve 5FU + oxiplatin + irinotecan objectively show significant increase overall survival patient metastatic pancreatic adenocarcinoma compare gemcitabine alone ( median 11.1 month versus 6.8 month , HR = 0.57 [ 0.45 - 0.73 ] p &lt; 0.0001 ) . The response rate progression-free survival ( PFS ) also improve triple therapy ; response rate 31.6 % versus 9.4 % p &lt; 0.001 median PFS 6.4 month versus 3.3 month p &lt; 0.001 , respectively . The adverse event observe triple therapy occur frequently , febrile neutropaenia ( 5.4 % ) , need treat growth factor ( G-CSF 42.5 % patient ) . Haematological digestive toxicity also high : grade 3-4 neutropaenia observe 45.7 % patient FOLFIRINOX arm 18.7 % patient gemcitabine arm ( p = 0.0001 ) ; vomit note 14.5 % patient FOLFIRINOX arm 4.7 % gemcitabine arm ( p = 0.002 ) . Quality life improve FOLFIRINOX arm . Due histological , therapeutic prognostic similarity pancreatic bile duct cancer , interest assess triple therapy compare current reference treatment bile duct cancer : gemcitabine combine cisplatin ( GEMCIS ) . Due know high level toxicity triple therapy ( digestive haematological ) , investigator modify conventional FOLFIRINOX regimen ( mFOLFIRINOX ) remove 5-FU bolus D1 cycle . This modification regimen would appear decrease efficacy treatment .</detailed_description>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<criteria>WHO 0 1 Age ≥ 18 year Tumour intrahepatic extrahepatic ( and/or hilar ) bile duct , gallbladder Measurable abdominal metastasis ( least lesion &gt; 10 mm ) and/or measurable , unresectable primary tumour Disease proven histopathology cytology ( metastasis primary tumour ) If abdominal metastasis , unresectability must confirm hepatobiliary surgeon multidisciplinary team ( MDT ) meeting Bilirubin &lt; 1.5 N ( endoscopic trance hepatic optimum biliary drainage , necessary ) , AST ALT &lt; 10N Serum creatinine &lt; 130 µmol/L , creatinine clearance &gt; 60 mL/min Neutrophils ≥ 1500/mm3 platelet ≥ 75,000/mm3 Prothrombin index &gt; 70 % Serum albumin &gt; 25 g/L Patient register social security scheme ( include CMU ) Signed informed consent form Nonmeasurable metastasis primary tumour Ampullary carcinoma cancer pancreas infiltration bile ducts mixed tumour ( hepatocholangiocarcinoma ) Chemotherapy and/or radiotherapy within last 4 month Other malignant tumour except situ basal cell carcinoma curatively treat carcinoma uterine cervix malignant tumour treat consider cure least 5 year Major comorbidity factor ( unstable angina , myocardial infarction occur within last 6 month , heart failure ≥2 accord NYHA classification , uncontrolled high blood pressure ) Woman pregnant breastfeeding , patient either sex childbearing age use adequate contraceptive method Not able undergo trial medical followup geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bile Duct Cancer</keyword>
	<keyword>phase II/III</keyword>
	<keyword>Modified folfirinox</keyword>
	<keyword>Gemcis</keyword>
</DOC>